Neogen Corporation's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2026 to a ratio of 6.21, above the company average. This is a clear sign of healthy business climate in the In Vitro & In Vivo Diagnostic Substances industry and improving liquidity at their respective customers, during the third quarter 2026. Average receivable collection period, for the Neogen in Feb 28 2026 quarter, has decreased to 59 days, compared to 61 days, in the Nov 30 2025 quarter.

If we take a look into Healthcare sector 276 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 2116, from overall ranking in the second quarter 2026 at 2468.

What is Receivable Turnover Ratio?
What is Neogen Corporation Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NEOG Receivables Turnover Ratio	(Feb 28 2026) III. Quarter	(Nov 30 2025) II. Quarter	(Aug 31 2025) I. Quarter	(May 31 2025) IV. Quarter	(Feb 28 2025) III. Quarter
Y / Y Receivable Change	-14.35 %	-19.55 %	-17.41 %	-11.34 %	-7.79 %
Y / Y Revenue Change	-4.21 %	-2.45 %	-3.67 %	-4.2 %	-3.34 %
Receivable Turnover Ratio (TTM)	6.21	6.03	5.76	5.54	5.44
NEOG's Total Ranking	# 2116	# 2468	# 2592	# 614	# 2693
Accounts Receivable average collection period days	59	60	63	66	67
Seq. Receivable Change	3.86 %	-4.66 %	-9.73 %	-4.18 %	-2.45 %
Seq. Revenue Change	-6.09 %	7.52 %	-7.88 %	2.99 %	-4.37 %

Receivable Turnover Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 9
Healthcare Sector	# 277
Overall Market	# 2116

Receivable Turnover Ratio Statistics
High	Average	Low
6.33	5.49	5.07
(Aug 31 2023)		(May 31 2020)

NEOG Company Profile • Back to NEOG Efficiency Comparisons • Compare NEOG Receivables Turnover Ratio to its Competitors

Financial Statements
Neogen's Accounts Receivable	$ 137 Millions	Visit NEOG's Balance sheet
Neogen's Sales TTM	$ 872 Millions	Visit NEOG's Income Statement
Sources of NEOG's Revenues		Visit NEOG's Sales by Geography

Other Accounts Receivable Turnover Ratios
In Vitro & In Vivo Diagnostic Substances Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NEOG's Receivable Turnover Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NEOG's Growth Rates	NEOG's Roa	NEOG's Inventory Turnover Ratio	NEOG's Dividend Comparisons
NEOG's Profitability Ratios	NEOG's Roi	NEOG's Asset Turnover Ratio	NEOG's Dividend Growth
NEOG's Valuation Ratios	NEOG's Roe	NEOG's Financial Strength Ratios	NEOG's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Feb 28 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Feb 28 2026	Receivable at quarter ending Feb 28 2026
Nutriband Inc	16.79	$ 1.803 Millions	$ 0.107 Millions
Bioadaptives Inc	16.64	$ 0.024 Millions	$ 0.001 Millions
Premier Air Charter Holdings Inc	16.33	$ 33.205 Millions	$ 2.033 Millions
Bioage Labs Inc	15.90	$ 10.316 Millions	$ 0.649 Millions
Nurix Therapeutics Inc	15.11	$ 71.779 Millions	$ 4.750 Millions
Lexicon Pharmaceuticals Inc	14.91	$ 69.643 Millions	$ 4.670 Millions
Qhslab Inc	14.80	$ 2.775 Millions	$ 0.188 Millions
Nexgel Inc	14.19	$ 10.382 Millions	$ 0.732 Millions
Sutro Biopharma Inc	14.04	$ 99.608 Millions	$ 7.095 Millions
Precipio inc	13.93	$ 25.831 Millions	$ 1.854 Millions
China Pharma Holdings Inc	13.86	$ 3.992 Millions	$ 0.288 Millions
Talkspace Inc	13.67	$ 239.269 Millions	$ 17.501 Millions
Marpai Inc	13.59	$ 17.125 Millions	$ 1.261 Millions
Amneal Pharmaceuticals Inc	13.56	$ 3,045.530 Millions	$ 224.634 Millions
Corcept Therapeutics Inc	13.20	$ 769.096 Millions	$ 58.264 Millions
Rosecliff Acquisition Corp I	13.19	$ 20.547 Millions	$ 1.557 Millions
Xoma Royalty Corporation	13.05	$ 48.555 Millions	$ 3.720 Millions
Mannkind Corporation	13.00	$ 360.783 Millions	$ 27.757 Millions
Lifestance Health Group Inc	12.74	$ 1,494.791 Millions	$ 117.296 Millions
Chemed Corporation	12.73	$ 2,540.548 Millions	$ 199.626 Millions
Milestone Scientific Inc	12.69	$ 8.337 Millions	$ 0.657 Millions
Lftd Partners Inc	12.55	$ 36.955 Millions	$ 2.945 Millions
Clene Inc	12.47	$ 0.134 Millions	$ 0.011 Millions
Skinhealth Systems Inc	12.27	$ 295.223 Millions	$ 24.052 Millions
Cytokinetics Incorporated	12.16	$ 105.815 Millions	$ 8.702 Millions
Precision Biosciences Inc	11.94	$ 45.073 Millions	$ 3.776 Millions
Teladoc Health Inc	11.94	$ 2,514.453 Millions	$ 210.660 Millions
Option Care Health Inc	11.65	$ 5,666.577 Millions	$ 486.439 Millions
Ensysce Biosciences Inc	11.55	$ 4.708 Millions	$ 0.407 Millions
Crinetics Pharmaceuticals Inc	11.52	$ 18.069 Millions	$ 1.569 Millions

Date modified: 2026-09-08T15:11:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.